Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but ...

Drugmakers are lobbying Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the ...

UPS declined to comment. FedEx did not directly address the issue. Pharmaceutical products have long been spared from trade ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

The recent imposition of a 27 per cent reciprocal tariff on Indian exports by the United States, while exempting the ...

Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and pharma practices, blurring traditional industry lines. Key findings are powered by ...

Pharmaceutical products will be spared from sweeping tariffs on major U.S. trade partners for now, a small victory for drug companies who have been lobbying for an exemption from levies.

The talks between the administration and the industry, which have been taking place behind closed doors, have given some ...